Low- and ultra-low-molecular-weight heparins

Best Practice and Research: Clinical Haematology

Volumn 17, Issue 1, 2004, Pages 77-87

  Kakkar, Ajay K ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Heparin; Heparin like drugs; Low molecular weight heparin; Venous and arterial thromboembolic disease

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LACTOBIONIC ACID; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PENTASACCHARIDE; PENTOSAN POLYSULFATE; POLYSULFONE; SULFONIC ACID DERIVATIVE; THROMBIN; THROMBOCYTE FACTOR 4; TINZAPARIN;

ARTERY THROMBOSIS; ARTICLE; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG PURIFICATION; DRUG SCREENING; HEART MUSCLE ISCHEMIA; HEMATOMA; HIGH RISK PATIENT; HUMAN; PHLEBITIS; PRIORITY JOURNAL; SURGICAL PATIENT; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 2942676484     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.03.001     Document Type: Review

References (43)

1. Kakkar VV, Corrigan TP, Spindler J, et al. Efficacy of low doses of heparin in prevention of deep vein thrombosis after major surgery. Lancet 1972; 2: 101-106.
2. Kakkar VV, Corrigan TP, Foassard DP, et al. Prevention of fatal postoperative pulmonary embolism by low doses of heparin: an International Multicentre Trial. Lancet 1975; 2: 45-51.
3. Lane DA, McGregor IR, Vanross M, et al. Molecular weight dependence of the anticoagulant properties of heparin. Thrombosis and Haemostasis 1979; 16: 651-662.
4. Weitz J. Low molecular weight heparins. The New England Journal of Medicine 1997; 337: 688-698.
5. Kakkar VV, Djazaeri B, Folk J, et al. Low molecular weight heparin and prevention of postoperative deep vein thrombosis. BMJ 1982; 284: 375-382.
6. Koch A, Bouges S, Ziegler S, et al. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention. The British Journal of Surgery 1997; 84: 750-759.
7. Nurhomed MT, Rosendaal FR, Buller HR, et al. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1991; 340: 152-156.
8. Leizorovicz A, Simonneau G, Decousus H & Boissel JP. Comparison of efficacy of low molecular weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: a meta-analysis. BMJ 1994; 309: 299-304.
9. Gould MK, Dembitzer AD, Doyle RL, et al. Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomised, controlled trials. Annals of Internal Medicine 1999; 130: 800-809.
10. Breddin HK, Hach-Wunderle V, Nakov R & Kakkar VV. Effects of low molecular weight heparin on thrombus regression and recurrent thromboembolism in patients with deep vein thrombosis. The New England Journal of Medicine 2001; : 626-631.
11. Hull R, Pineo G & Mah A. Long term low molecular weight heparin treatment versus oral anticoagulant therapy for proximal deep vein thrombosis. Blood 2000; 96: 449.
12. Levine M, Gent M, Hirsh J, et al. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. The New England Journal of Medicine 1996; 334: 677-681.
13. Koopman MM, Prandoni P, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital compared with subcutaneous low molecular weight heparin administered at home. The Tasman Study Group. The New England Journal of Medicine 1996; 334: 682-687.
14. The Columbus Investigators, Low molecular weight heparin in the treatment of patients with venous thromboembolism. The New England Journal of Medicine 1997; 337: 657-662.
15. Harenberg J, Roebruck P, Heene DL & The HESIM Group. Subcutaneous low molecular weight heparin (IMM) against unfractionated (UF) heparin for prophylaxis of thromboembolism in medical patients. Annals of Hematology 1995; 68(supplement 11): 51.
16. Samama MM, Cohen AT, DarmonJY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. The New England Journal of Medicine 1999; 341: 793-800.
17. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus R Goldhaber SZ for the PREVENT Medical Thromboprophylaxis Study Group. A randomised placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. ISTH abstract OC396. Presented on 18 July 2003 in Birmingham, UK.
18. FRISC study, Low molecular weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-568.
19. ESSENCE study, A comparison of low molecular weight heparin with unfractionated heparin investigators for unstable coronary artery disease. The New England Journal of Medicine 1997; 337: 447-452.
20. Thodiyil PA & Kakkar AK. Variation in relative risk of venous thromboembolism in different cancer. Thrombosis and Hoemostasis 2002; 87: 1076-1077.
21. Kakkar VV, How CT, Nicolaides AN, et al. Deep vein thrombosis of the leg: is there a high risk group? American Journal of Surgery 1970; 120: 527-530.
22. Kakkar AK, Haas S, Walsh D, et al. Prevention of perioperative venous thromboembolism: outcome after cancer and non-cancer surgery. Thrombosis and Hoemostasis 2001.
23. Eikelboom JW, Quinlan DJ & Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta analysis of the randomised trials. Lancet 2001; 358: 9-15.
24. Bergqvist D, Agnelli G, Coehn AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. The New England Journal of Medicine 2002; 346: 975-980.
25. Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
26. Kakkar AK, Breddin H-K, Kakkar VV & Kadziola Z. Treatment of deep vein thrombosis in cancer: a comparison of unfractionated low molecular weight heparin. Blood 2002; 96: 491(a).
27. Lee AYY, Levine HN, Baker RI, et al. Low molecular weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer. The New England Journal of Medicine 2003; 125: 1-7.
28. Green D, Hull RD, Brant R & Pineo GE Lower mortality in cancer patients treated with low molecular weight versus standard heparin. Lancet 1992; 339: 1476.
29. Siragusa S, Cosmi B, Novella R, Hirsh J & Ginsberg J. Low molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. The American Journal of Medicine 1996; 100: 269-277.
30. Kakkar AK, Levire HN, Kadziola Z, Lemoire NR, et al. Low molecular weight heparin (LMWH) therapy and survival in advanced cancer. J Clin Oncol 2004; in press.
31. Lee AYY. ASCO abstract book. 2003.
32. Altinbas HSC, Er O, Ozkan M, et al, Prospective randomised study of epirubicine cyclophosphamide and vincristine. Combination chemotherapy (CEV), low molecular weight heparin (LMWH) in small cell lung cancer (SCLC). ASCO annual meeting 2001. Abstract no. 1280.
33. Klerk CR Otten JMMB & Buller HR. Malignancy and low molecular weight heparin therapy: the MALT trial. Journal of Thrombosis and Haemostasis 2003; 1(supplement 1). Abstract no. OC 195.
34. Petitou M, Lormeau JC & Choay J. Chemical synthesis of glycosaminoglycans: new approaches to antithrombotic drugs. Nature 1991; 350(6319m, supplement): 30-33.
35. Lassen MR, Bauer KA, Eriksson Bl, Turpie AG & The European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-1720.
36. Turpie AG, Bauer KA, Eriksson BI, Lassen MR & The PENTATHLON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721-1726.
37. Bauer KA, Eriksson BI, Lassen MR, Turpie AG & The Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. The New England Journal of Medicine 2001; 345: 1305-1310.
38. Eriksson BI, Bauer KA, Lassen MR, Turpie AG & The Steering Committee of the Pentasaccharide in Hip Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip fracture surgery. The New England Journal of Medicine 2001; 345: 1298-1304.
39. Turpie AGG, Bauer KA, Eriksson BI, Lassen MID & The Steering Committee of the Pentasaccharide Orthopaedic Prophylaxis Studies. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery. Archives of Internal Medicine 2002; 162: 1833-1840.
40. Eriksson BI, Lassen MR & The Pentasaccharide in Hip Fracture Surgery Plus (PENTHIFRA Plus) Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery. Archives of Internal Medicine 2003; 163: 1337-1342.
41. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. The New England Journal of Medicine 2003; 349: 1695-1702.
42. Petitou M, Herault J-P, Bernat A, et al. Letters Nature 1999; 398: 417.
43. Scully MF & Kakkar VV. Identification of heparin cofactor II as the principle plasma cofactor for pentosan polysulfate (SP54). Thrombosis and Hoemostasis 1991; 17(supplement 2): 181-185.